Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

1,357

Participants

Timeline

Start Date

April 16, 2024

Primary Completion Date

September 8, 2025

Study Completion Date

January 22, 2026

Conditions
Asthma
Interventions
DRUG

Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate

Participants will receive FF/UMEC/VI

DRUG

Inhaled corticosteroids/long-acting beta-2 agonists

Participants will receive ICS/LABA

Trial Locations (74)

807

GSK Investigational Site, Kaohsiung City

1878

GSK Investigational Site, Quilmes

2000

GSK Investigational Site, Rosario

2035

GSK Investigational Site, Sydney

2148

GSK Investigational Site, Blacktown

2259

GSK Investigational Site, Kanwal

2450

GSK Investigational Site, Coffs Harbour

2617

GSK Investigational Site, Bruce

3260

GSK Investigational Site, Concepción del Uruguay

4006

GSK Investigational Site, Brisbane

5577

GSK Investigational Site, Mendoza

6017

GSK Investigational Site, Osborne Park

6163

GSK Investigational Site, Spearwood

12553

GSK Investigational Site, New Windsor

15241

GSK Investigational Site, Pittsburgh

19140

GSK Investigational Site, Philadelphia

20852

GSK Investigational Site, New Orleans

28273

GSK Investigational Site, Charlotte

28801

GSK Investigational Site, Asheville

29303

GSK Investigational Site, Spartanburg

29732

GSK Investigational Site, Rock Hill

32308

GSK Investigational Site, Tallahassee

32819

GSK Investigational Site, Orlando

33126

GSK Investigational Site, Miami

33135

GSK Investigational Site, Miami

33169

GSK Investigational Site, North Miami Beach

33173

GSK Investigational Site, Miami

33406

GSK Investigational Site, Palm Springs

33952

GSK Investigational Site, Port Charlotte

40447

GSK Investigational Site, Taichung

45231

GSK Investigational Site, Cincinnati

48088

GSK Investigational Site, Warren

59804

GSK Investigational Site, Missoula

61761

GSK Investigational Site, Normal

68046

GSK Investigational Site, Papillion

72205

GSK Investigational Site, Little Rock

75225

GSK Investigational Site, Dallas

77701

GSK Investigational Site, Beaumont

92663

GSK Investigational Site, Newport Beach

04401

GSK Investigational Site, Bangor

08221

GSK Investigational Site, Linwood

C1128AAF

GSK Investigational Site, Buenos Aires

C1192AAW

GSK Investigational Site, Buenos Aires

C1425BEN

GSK Investigational Site, Buenos Aires

FVH1425

GSK Investigational Site, Buenos Aires

S2000DBS

GSK Investigational Site, Rosario

N8X 1T3

GSK Investigational Site, Windsor

G9A 4P3

GSK Investigational Site, Trois-Rivières

802-0083

GSK Investigational Site, Fukuoka

820-8505

GSK Investigational Site, Fukuoka

509-6134

GSK Investigational Site, Gifu

730-0853

GSK Investigational Site, Hiroshima

651-0053

GSK Investigational Site, Hyōgo

761-8073

GSK Investigational Site, Kagawa

890-0053

GSK Investigational Site, Kagoshima

252-0143

GSK Investigational Site, Kanagawa

860-8556

GSK Investigational Site, Kumamoto

862-0965

GSK Investigational Site, Kumamoto

790-0925

GSK Investigational Site, Matsuyama

880-2112

GSK Investigational Site, Miyazaki

889-4304

GSK Investigational Site, Miyazaki

940-0087

GSK Investigational Site, Nagaoka-Shi

950-0088

GSK Investigational Site, Niigata

831-0016

GSK Investigational Site, Okawa-shi

Unknown

GSK Investigational Site, Ōita

105-0001

GSK Investigational Site, Tokyo

142-8666

GSK Investigational Site, Tokyo

145-0063

GSK Investigational Site, Tokyo

157-0066

GSK Investigational Site, Tokyo

160-0017

GSK Investigational Site, Tokyo

223-0053

GSK Investigational Site, Yokohama

03080

GSK Investigational Site, Seoul

133-792

GSK Investigational Site, Seoul

158-710

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY